Bart Steiner
Impact in
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 7
- CRISPR and Genetic Engineering 2
- Oncology 7
- Cancer-related Molecular Pathways 4
- Cytokine Signaling Pathways and Interactions 2
- Co-authors
- Kamal D. Puri (8 shared papers)Brian J. Lannutti (6 shared papers)Adam Kashishian (6 shared papers)Sarah Meadows (5 shared papers)Amy J. Johnson (3 shared papers)Roger G. Ulrich (3 shared papers)John C. Byrd (3 shared papers)Neill A. Giese (5 shared papers)
- Journals
- The Journal of Immunology (3 papers)Blood (3 papers)Molecular and Cellular Biology (2 papers)Journal of Biological Chemistry (2 papers)Cancer Research (2 papers)
- Partner nations
- United StatesItalySwitzerland
In The Last Decade
Bart Steiner
18 papers receiving 1.0k citations
Bart Steiner's Hit Papers
Peers
Comparison fields: 5 of 75
- Genetics 445
- Pathology and Forensic Medicine 290
- Immunology 301
- Hematology 134
- Oncology 197
Countries citing papers authored by Bart Steiner
This map shows the geographic impact of Bart Steiner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Steiner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Steiner more than expected).
Fields of papers citing papers by Bart Steiner
This network shows the impact of papers produced by Bart Steiner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Steiner. The network helps show where Bart Steiner may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart Steiner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Hit paper breakdown → | 2010 | 617 |
| 2 | 2000 | 122 | |
| 3 | 2020 | 77 | |
| 4 | 2000 | 64 | |
| 5 | 2014 | 39 | |
| 6 | 2013 | 36 | |
| 7 | 2016 | 27 | |
| 8 | 1990 | 22 | |
| 9 | 2016 | 18 | |
| 10 | 1990 | 17 | |
| 11 | 2009 | 7 | |
| 12 | 1984 | 6 | |
| 13 | 2008 | 4 | |
| 14 | 2022 | 3 | |
| 15 | 2009 | 2 | |
| 16 | 2009 | 1 | |
| 17 | 2011 | 1 | |
| 18 | 1969 | 1 | |
| 19 | 1978 | 0 |
About Bart Steiner
Bart Steiner is a scholar working on Molecular Biology, Oncology, Genetics, Immunology and Cardiology and Cardiovascular Medicine, having authored 19 papers that have together received 1.1k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Cancer-related Molecular Pathways (4 papers), Animal Genetics and Reproduction (2 papers), Hormonal Regulation and Hypertension (2 papers), Chromosomal and Genetic Variations (2 papers), Cytokine Signaling Pathways and Interactions (2 papers) and CRISPR and Genetic Engineering (2 papers). The work is most often cited by research in Genetics (445 citations), Pathology and Forensic Medicine (290 citations), Immunology (301 citations), Hematology (134 citations) and Oncology (197 citations). Bart Steiner has collaborated with scholars based in United States, Italy and Switzerland. Frequent co-authors include Kamal D. Puri, Brian J. Lannutti, Adam Kashishian, Sarah Meadows, Amy J. Johnson, Roger G. Ulrich, John C. Byrd, Neill A. Giese, Sarah E. M. Herman and Jeffrey Tyner. Their work appears in journals such as The Journal of Immunology, Blood, Molecular and Cellular Biology, Journal of Biological Chemistry and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.